BNET Industries

Sciele Pharma Inc.

(SCRX) is in the Pharma Industry

Last Fiscal Year Sales:$382.2M
  • Public
  • US
Dow Jones Description

Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on Cardiovascular, Diabetes, Women's Health and Pediatrics. The Company's Cardiovascular and Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and Type 2 diabetes; its Women's Health products are designed to improve the health and well-being of women and mothers and their babies; and its Pediatrics products treat allergies, asthma, coughs and colds, and attention deficit/hyperactivity disorder (ADHD). Founded in 1992 and headquartered in Atlanta, Georgia, Sciele Pharma employs more than 1,000 people. The Company's success is based on placing the needs of patients first, improving health and quality of life, and implementing its business platform - an Entrepreneurial Spirit, Innovation, Execution Excellence, Simplicity, and Teamwork. On October 9,2008, Shionogi & Co., Ltd. ("Shionogi") and Sciele Pharma, Inc. ("Sciele") announced the completion of Shionogi's acquisition of Sciele for $31.00 USD per share in cash. Shionogi completed the acquisition through a cash tender offer followed by short-form merger of the indirect wholly owned subsidiary of Shionogi with and into Sciele. Sciele is now an indirect wholly owned subsidiary of Shionogi.

Number of Employees 920
Contact Information

5 Concourse Pkwy Ste 1800

Atlanta, Georgia 30328

orapredsmallpac...

(770) 442-9707

NAICS Code Drugs and Druggists' Sundries Merchant Wholesalers: 424210

Recent Events

  • Bitter pill for Atlanta: 200 more pharma jobs lost

    10/10/09 - Merger / Acquisition - View Story

  • Willkie Farr and Paul Weiss on $2.6 Billion Japanese Pharma Deal

    9/03/09 - Merger / Acquisition - View Story

  • UPDATE 1-Plethora sells lead drug rights, cuts debt by 90 pct

    5/26/09 - New Investment - View Story

  • Four Firms Cash In on Pharma M&A

    5/22/09 - Merger / Acquisition - View Story

  • InVasc Therapeutics Announces Executive and Board Appointments

    5/18/09 - Mgmt. Change Entering - COO - View Story

News & Analysis

sciele pharma inc. - All News and Analysis

  • Sciele Pharma Inc. Q2 2008 Earnings Call Transcript

    Seeking Alpha - 2008-07-30

    Question-and-Answer SessionOperator Thank you. Operators Instructions. Our first question this afternoon will come from Donald Ellis with Thomas Weisel Partners. Donald Ellis - Thomas Weisel Partners Thank you and good afternoon guys. Darrell I just wanted to kind of reconcile the old versus new guidance and the way I'd...

    Tags: Sciele Pharma Inc.

  • Sciele Pharma, Inc. Q1 2008 Earnings Call Transcript

    Seeking Alpha - 2008-04-30

    Question-and-Answer SessionOperator Thank you. Operator Instructions. And, we will go first to Donald Ellis with Thomas Weisel Partners. Donald Ellis Good afternoon guys. I have a few questions. First for, I guess are on Sular. Can you just kind of give us an update...

    Tags: Sciele Pharma Inc.

  • Sciele Pharma Inc. Q4 2007 Earnings Call Transcript

    Seeking Alpha - 2008-03-07

    Question-and-Answer Session Operator Operator Instructions And we will go first to Annabel Samimy - UBS. Annabel Samimy - UBS On the Sular, have you started drawing down inventories before January? It seems like the cardiovascular was a little bit lighter than we would have expected....

    Tags: Sciele Pharma Inc.

  • Sciele Pharma Q3 2007 Earnings Call Transcript

    Seeking Alpha - 2007-10-30

    Question-and-Answer SessionOperator Operator Instructions. We'll go first to Adam Greene, JP Morgan. Adam Greene - JP Morgan Good evening, everyone. Darrell Borne Hi Adam, how are you? Adam Greene - JP Morgan Good. Few questions for you Darrell, on the guidance, you mentioned the excluding one time charges for...

    Tags: Sciele Pharma Inc.